Tyroserleutide (YSL) is primarily researched for its potential applications in cancer therapy. It has shown promising results in inhibiting the growth of certain types of cancer cells, particularly liver cancer. Studies suggest that it may enhance the effectiveness of chemotherapy by targeting specific pathways involved in tumor progression. Additionally, YSL is being explored for its role in reducing tumor metastasis, which could improve patient outcomes in advanced stages of cancer. Its mechanism of action involves modulating cellular processes that are crucial for cancer cell survival and proliferation. Further research is ongoing to fully understand its therapeutic potential and optimize its use in clinical settings.